Exagen Inc. Appoints Chas McKhann to Board of Directors
Exagen Inc. (NASDAQ: XGN), a provider of autoimmune testing solutions, has appointed Chas McKhann to its Board of Directors, effective July 17, 2025. McKhann brings over 25 years of life sciences industry experience, having served as President and CEO of Silk Road Medical and Apollo Endosurgery, both successfully acquired by Boston Scientific.
McKhann's extensive background includes roles as Chief Commercial Officer at Torax Medical and Intersect ENT, along with significant experience in leading turnaround and transformational growth at medical technology companies. He holds degrees from Stanford University, including an M.B.A.
Exagen Inc. (NASDAQ: XGN), fornitore di soluzioni per test autoimmuni, ha nominato Chas McKhann nel suo Consiglio di Amministrazione, a partire dal 17 luglio 2025. McKhann vanta oltre 25 anni di esperienza nel settore delle scienze della vita, avendo ricoperto il ruolo di Presidente e CEO presso Silk Road Medical e Apollo Endosurgery, entrambe acquisite con successo da Boston Scientific.
Il suo ampio background include posizioni come Chief Commercial Officer presso Torax Medical e Intersect ENT, oltre a una significativa esperienza nella guida di processi di rilancio e crescita trasformativa in aziende di tecnologia medica. Ha conseguito lauree presso la Stanford University, incluso un M.B.A.
Exagen Inc. (NASDAQ: XGN), proveedor de soluciones para pruebas autoinmunes, ha nombrado a Chas McKhann en su Junta Directiva, con efecto a partir del 17 de julio de 2025. McKhann aporta más de 25 años de experiencia en la industria de ciencias de la vida, habiendo sido Presidente y CEO de Silk Road Medical y Apollo Endosurgery, ambas adquiridas exitosamente por Boston Scientific.
Su amplia trayectoria incluye cargos como Director Comercial en Torax Medical e Intersect ENT, junto con una experiencia significativa liderando procesos de recuperación y crecimiento transformacional en empresas de tecnología médica. Posee títulos de la Universidad de Stanford, incluyendo un M.B.A.
Exagen Inc. (NASDAQ: XGN)는 자가면역 검사 솔루션 제공업체로서, 2025년 7월 17일부로 Chas McKhann을 이사회 멤버로 임명했습니다. McKhann은 생명과학 산업에서 25년 이상의 경력을 보유하고 있으며, Silk Road Medical과 Apollo Endosurgery에서 사장 겸 CEO로 재직했으며, 두 회사 모두 Boston Scientific에 성공적으로 인수되었습니다.
그의 폭넓은 경력에는 Torax Medical과 Intersect ENT에서 최고 상업 책임자(Chief Commercial Officer)로 근무한 경험과 의료기술 기업에서의 구조조정 및 혁신적 성장 리더십 경험이 포함됩니다. 그는 스탠포드 대학교에서 학위를 받았으며, MBA 학위도 소지하고 있습니다.
Exagen Inc. (NASDAQ: XGN), fournisseur de solutions de tests auto-immuns, a nommé Chas McKhann au sein de son conseil d'administration, à compter du 17 juillet 2025. McKhann apporte plus de 25 ans d'expérience dans l'industrie des sciences de la vie, ayant été président et CEO de Silk Road Medical et Apollo Endosurgery, toutes deux acquises avec succès par Boston Scientific.
Son parcours étendu inclut des postes de Chief Commercial Officer chez Torax Medical et Intersect ENT, ainsi qu'une expérience significative dans la conduite de redressements et de croissance transformationnelle au sein d'entreprises de technologie médicale. Il est diplômé de l'Université de Stanford, avec notamment un M.B.A.
Exagen Inc. (NASDAQ: XGN), Anbieter von Autoimmun-Testlösungen, hat Chas McKhann mit Wirkung zum 17. Juli 2025 in seinen Vorstand berufen. McKhann bringt über 25 Jahre Erfahrung in der Life-Sciences-Branche mit und war Präsident und CEO von Silk Road Medical sowie Apollo Endosurgery, die beide erfolgreich von Boston Scientific übernommen wurden.
Sein umfangreicher Hintergrund umfasst Positionen als Chief Commercial Officer bei Torax Medical und Intersect ENT sowie bedeutende Erfahrung in der Leitung von Turnaround- und Transformationsprozessen bei Medizintechnikunternehmen. Er besitzt Abschlüsse von der Stanford University, darunter einen M.B.A.
- Appointment of experienced leader with 25+ years in life sciences
- Track record of successful company acquisitions and shareholder returns
- Strong commercial expertise in medical technology sector
- None.
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025.
Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholder returns. Previously, Mr. McKhann served as Chief Commercial Officer at Torax Medical and Intersect ENT. Mr. McKhann holds a B.A. in Political Science and an M.B.A. from Stanford University.
“I couldn’t be more excited to welcome Chas to the Board of Directors at Exagen. His exceptional leadership across multiple innovative life science companies and deep commercial expertise will be invaluable as we continue to drive growth and advance patient care,” said John Aballi, President and CEO of Exagen.
“I’m honored to join the Board of Directors at Exagen, a company transforming autoimmune diagnostics through innovation and dedication to patient care. I look forward to working alongside the leadership team and fellow board members to help drive strategic growth and create long-term value for patients, providers, and shareholders,” said McKhann.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow @ExagenInc on X.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential utility and effectiveness of Exagen’s services and testing solutions; the expected benefits of Mr. McKhann’s position with Exagen; potential shareholder value and growth and 2025 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
Who is Chas McKhann and why did Exagen (XGN) appoint him to their board?
What is Chas McKhann's previous experience before joining Exagen's board?
When does Chas McKhann's appointment to Exagen's board take effect?
What is Exagen (XGN) and what do they do?
